{"preliminary_commentary":{"by_channel":{"x_thread":3,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT05808608","nct_id":"NCT05808608","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05808608. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Subjects in this group will receive AK104 (RP2D, administered intravenously) plus Axitinib 5 mg bid, administered orally.","label":"Combination treatment group","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-06","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma","First-line Treatment","Non Clear Cell Renal Cell Carcinoma","Sarcomatoid Renal Cell Carcinoma"],"enrollment":{"count":37,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"AK104","otherNames":[],"type":"DRUG"},{"name":"Axitinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-04-07","lead_sponsor":"Hao Zeng","official_title":"Efficacy and Safety of First-Line Cadonilimab Plus Axitinib in Patients With Advanced Special Pathological Type Renal Cell Carcinoma: A Prospective, Multi-center, Phase Ib/II Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase Ib Safety Assessment","timeFrame":"3 years"},{"measure":"Phase II Efficacy Assessment: ORR","timeFrame":"3 years"}],"references":[{"citation":"Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, Fernandez-Pello S, Giles RH, Hofmann F, Hora M, Klatte T, Kuusk T, Lam TB, Marconi L, Powles T, Tahbaz R, Volpe A, Bex A. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022 Oct;82(4):399-410. doi: 10.1016/j.eururo.2022.03.006. Epub 2022 Mar 26.","pmid":"35346519","type":"BACKGROUND"},{"citation":"Diaz-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020 Dec;16(12):721-735. doi: 10.1038/s41581-020-0316-3. Epub 2020 Jul 30.","pmid":"32733094","type":"BACKGROUND"},{"citation":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.","pmid":"29562145","type":"BACKGROUND"},{"citation":"2022 ASCO # Oral abstract 106.","pmid":null,"type":"BACKGROUND"}],"start_date":{"date":"2023-11-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT05808608"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05808608"}